| 國立成功大學 |
2023 |
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
|
Sequist, L.V.;Yang, J.C.-H.;Yamamoto, N.;O'Byrne, K.;Hirsh, V.;Mok, T.;Geater, S.L.;Orlov, S.;Tsai, C.-M.;Boyer, M.;Su, W.-C.;Bennouna, J.;Kato, T.;Gorbunova, V.;Lee, K.H.;Shah, R.;Massey, D.;Zazulina, V.;Shahidi, M.;Schuler, M. |
| 臺大學術典藏 |
2022-09-15T01:08:58Z |
A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies
|
Yamamoto N.; Ryoo B.-Y.; Keam B.; Kudo M.; Chia-Chi Lin; Kunieda F.; Ball H.A.; Moran D.; Komatsu K.; Takeda K.; Fukuda M.; Furuse J.; Morita S.; Doi T. |
| 臺大學術典藏 |
2022-09-15T01:08:48Z |
Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia—Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium
|
Shimizu T.; Kim D.-W.; Loong H.H.; Chia-Chi Lin; Ng M.C.H.; Yamamoto N.; Ma B.; Tan D.S.W. |
| 臺大學術典藏 |
2022-09-15T01:08:46Z |
Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan with concomitant ritonavir or itraconazole in patients with HER2-expressing advanced solid tumors
|
Takahashi S.; Karayama M.; Takahashi M.; Watanabe J.; Minami H.; Yamamoto N.; Kinoshita I.; Chia-Chi Lin; Im Y.-H.; Achiwa I.; Kamiyama E.; Okuda Y.; Lee C.; Bang Y.-J. |
| 臺大學術典藏 |
2022-08-10T02:37:41Z |
EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: Outcomes in Asian populations
|
Kim E.S.; Melosky B.; Park K.; Yamamoto N.; CHIH-HSIN YANG |
| 臺大學術典藏 |
2022-08-10T02:37:41Z |
Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial
|
CHIH-HSIN YANG; Mok T.S.K.; Lu S.; Nakagawa K.; Yamamoto N.; Shi Y.-K.; Zhang L.; Soo R.A.; Morita S.; Tamura T. |
| 臺大學術典藏 |
2022-06-27T07:01:36Z |
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
|
Yang J.C.-H.; Sequist L.V.; Geater S.L.; Tsai C.-M.; Mok T.S.K.; Schuler M.; Yamamoto N.; CHONG-JEN YU; Ou S.H.I.; Zhou C.; Massey D.; Zazulina V.; Wu Y.-L. |
| 臺大學術典藏 |
2022-03-15T05:39:22Z |
The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcoma
|
Heng M.; Gupta A.; Chung P.W.; Healey J.H.; Vaynrub M.; Rose P.S.; Houdek M.T.; Lin P.P.; Bishop A.J.; Hornicek F.J.; Chen Y.-L.; Lozano-Calderon S.; Holt G.E.; Han I.; Biau D.; Niu X.; Bernthal N.M.; Ferguson P.C.; Wunder J.S.; Ueda T.; Kakunaga S.; Kawai A.; Sugiura H.; Kidani T.; Kunisasa T.; Ozaki T.; Ae K.; Nagano A.; Ohno T.; Hiraoka K.; Yamamoto N.; Tsuchiya H.; Matsumoto Y.; Yanagawa T.; Nakayama R.; Morioka H.; Kubo T.; Simose S.; Yamagami Y.; Yamamoto T.; Kawasaki M.; Torigoe T.; Yazawa Y.; Akiyama T.; Gokita T.; Manabe J.; Kaya M.; Emori M.; Nakamura T.; Matsumine A.; Sugihara S.; Yokouchi M.; Komiya S.; Suehara Y.; Takagi T.; Kawamoto T.; Wasa J.; Yonemoto T.; Ishii T.; Baba I.; Hoshi M.; Hamada K.; Naka N.; Sotobori T.; Araki N.; Okuma T.; Goto T.; Kobayashi H.; Kawano H.; Hosaka M.; Futani H.; Hiraga H.; Nishida Y.; Griffin A.; Razak A.R.A.; Shultz D.B.; Catton C.; Robinson S.; Patel S.R.; Lewis V.O.; Guadagnolo B.A.; DeLaney T.; Wang H.; Raskin K.; Callan A.K.; Henshaw R.; Isler M.; Mottard S.; Chen W.-M.; Traub F.; WEI-WU CHEN; Turcotte R.E.; Davidson D.; Tunn P.-U.; Loong H.; Ghert M.; Werier J.; Clarkson P.; Abraham J.A.; Japanese Musculoskeletal Oncology Group (JMOG), Soft Tissue Osteosarcoma International Collaborative (STOIC) |
| 臺大學術典藏 |
2022 |
Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer
|
Doki Y.; Ueno M.; CHIH-HUNG HSU; Oh D.-Y.; Park K.; Yamamoto N.; Ioka T.; Hara H.; Hayama M.; Nii M.; Komuro K.; Sugimoto M.; Tahara M. |
| 國立成功大學 |
2022 |
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC
|
Wu, Y.-L.;Lu, S.;Yang, J.C.-H.;Zhou, J.;Seto, T.;Ahn, M.-J.;Su, W.-C.;Yamamoto, N.;Kim, D.-W.;Paolini, J.;Usari, T.;Iadeluca, L.;Wilner, K.D.;Goto, K. |
